NOK 4.6
(-12.21%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 2.04 Million NOK | 86.82% |
2022 | 1.09 Million NOK | 26103.56% |
2021 | 4185.00 NOK | -99.95% |
2020 | 8.45 Million NOK | 18.12% |
2019 | 7.15 Million NOK | -40.66% |
2018 | 12.06 Million NOK | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 Q3 | - NOK | -100.0% |
2023 Q1 | - NOK | -100.0% |
2023 Q4 | 5.57 Million NOK | 0.0% |
2023 FY | 2.04 Million NOK | 86.82% |
2023 Q2 | 4.19 Million NOK | 0.0% |
2022 FY | 1.09 Million NOK | 26103.56% |
2022 Q4 | 1.09 Million NOK | 0.0% |
2022 Q2 | - NOK | 0.0% |
2021 Q2 | 16.33 Million NOK | 0.0% |
2021 FY | 4185.00 NOK | -99.95% |
2021 Q4 | 4185.00 NOK | 0.0% |
2020 FY | 8.45 Million NOK | 18.12% |
2020 Q4 | 8.45 Million NOK | 0.0% |
2019 FY | 7.15 Million NOK | -40.66% |
2018 FY | 12.06 Million NOK | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Aqua Bio Technology ASA | 7.12 Million NOK | 71.239% |
ArcticZymes Technologies ASA | 12.58 Million NOK | 83.726% |
BerGenBio ASA | 418 Thousand NOK | -390.127% |
Hofseth BioCare ASA | 136.78 Million NOK | 98.502% |
PCI Biotech Holding ASA | 319 Thousand NOK | -542.235% |
Thor Medical ASA | - NOK | -Infinity% |
Ultimovacs ASA | 3.71 Million NOK | 44.823% |